Goldman Sachs Starts Prime Medicine at Neutral With $22 Price Target - Marketscreener.com

2 years ago 34

Real-time Estimate Cboe BZX - 10:01 2022-11-14 americium EST
20.79	USD		-1.59%

11/14/2022 | 09:53am EST

MT Newswires 2022

All quality about PRIME MEDICINE, INC.

09:53a	Goldman Sachs Starts Prime Medicine astatine Neutral With $22 Price Target	MT
08:50a	JPMorgan Starts Prime Medicine astatine Overweight With $27 Price Target	MT
08:20a	Jefferies Starts Prime Medicine astatine Buy With $25 Price Target	MT
08:11a	Morgan Stanley Starts Prime Medicine astatine Equalweight With $23 Price Target	MT
10/27	Insider Buy: Prime Medicine	MT
10/27	Insider Buy: Prime Medicine	MT
10/25	Prime Medicine Completes Upsized $175 Million IPO	MT
10/24	Prime Medicine Announces Closing of Upsized Initial Public Offering	GL
10/21	Prime Medicine, Inc.(NasdaqGM:PRME) added to NASDAQ Compos..	CI
10/19	Prime Medicine, Inc. has completed an IPO successful the magnitude of $175.000006 million.	CI

Analyst Recommendations on PRIME MEDICINE, INC.

09:53a	Goldman Sachs Starts Prime Medicine astatine Neutral With $22 Price Target	MT
08:50a	JPMorgan Starts Prime Medicine astatine Overweight With $27 Price Target	MT
08:20a	Jefferies Starts Prime Medicine astatine Buy With $25 Price Target	MT

Financials (USD)

Chart PRIME MEDICINE, INC.

Duration : Period :

Technical investigation trends PRIME MEDICINE, INC.

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Neutral

Income Statement Evolution

Managers and Directors

Keith M. Gottesdiener	President, Chief Executive Officer & Director
Carman Alenson	Chief Accounting Officer & Vice President-Finance
Jeremy Duffield	Chief Scientific Officer
Ann L. Lee	Chief Technical Officer
Meredith Goldwasser	Head-Strategy & Corporate Operations

Sector and Competitors

		1st jan.	Capi. (M$)
	PRIME MEDICINE, INC.	0.00%	1 768


REGENERON PHARMACEUTICALS, INC.	16.30%	78 519
VERTEX PHARMACEUTICALS	38.10%	77 844
BIONTECH SE	-40.07%	37 549
WUXI APPTEC CO., LTD.	-28.01%	34 897
GENMAB A/S	13.92%	27 116